{"id":42815,"date":"2022-05-02T07:40:33","date_gmt":"2022-05-02T07:40:33","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=42815"},"modified":"2022-05-04T15:00:47","modified_gmt":"2022-05-04T15:00:47","slug":"fda-approves-dispersible-dolutegravir-abacavir-3tc-for-children","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/42815","title":{"rendered":"FDA approves dispersible dolutegravir\/abacavir\/3TC for children"},"content":{"rendered":"<div><strong>Simon Collins, HIV i-Base<\/strong><\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong>On 30 March 2022, the US FDA approved a single tablet regimen of dolutegravir\/abacavir\/3TC in a dispersible formulation for children weighing <span lang=\"EN-US\">10 kgs to 25 kgs.<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">This will provide a simpler and easier to take option for children living with HIV.<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">Reference<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">ViiV Healthcare. ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV. (30 March 2022).<br \/>\n<\/span><a href=\"https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv\">https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 30 March 2022, the US FDA approved a single tablet regimen of dolutegravir\/abacavir\/3TC in a dispersible formulation for children weighing 10 kgs to 25 kgs. This will provide a simpler and easier to take option &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-42815","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/42815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=42815"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/42815\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=42815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=42815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=42815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}